The management of uterine fibroids in women with otherwise unexplained infertility. J Obstet Gynaecol Can 2015 Mar;37(3):277-288.
The frequency of uterine leiomyomas. Am J Clin Pathol 1990 Oct;94(4):435-438.
High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003 Jan;188(1):100-107.
Relative overexpression of collagen type I and collagen type III messenger ribonucleic acids by uterine leiomyomas during the proliferative phase of the menstrual cycle. J Clin Endocrinol Metab 1994 Sep;79(3):900-906.
Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol 1989 Mar;160(3):637-641.
Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol 1995 Jan;172(1 Pt 1):14-18.
Rosai and Ackerman’s surgical pathology. 10th ed. Vol. 2. London: Mosby; 2011. p. 15.
Rare postpartum ruptured degenerated fibroid: a case report. J Obstet Gynaecol Res 2014 May;40(5):1423-1425.
Rupture of a degenerated uterine fibroid as a cause of acute abdomen: a case report. J Reprod Med 2013 Jan-Feb;58(1-2):72-74.
Case series: cystic degeneration in uterine leiomyomas. Indian J Radiol Imaging 2008 Feb;18(1):69-72.
Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obstet Gynecol 2009 Aug;21(4):318-324.
Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum Reprod 2009 Aug;24(8):1870-1879.
Mifepristone-induced amenorrhoea is associated with an increase in microvessel density and glucocorticoid receptor and a decrease in stromal vascular endothelial growth factor. Hum Reprod 2006 Sep;21(9):2312-2318.
Mifepristone: where do we come from and where are we going? Clinical development over a quarter of a century. Contraception 2010 Nov;82(5):442-452.
Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect. Fertil Steril 1995 Jul;64(1):187-190.
Treatment of uterine leiomyoma by two different doses of mifepristone. Zhonghua Fu Chan Ke Za Zhi 1996 Oct;31(10):624-626.
Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol 2003 Feb;101(2):243-250.
Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J Minim Invasive Gynecol 2005 May-Jun;12(3):227-233.
Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol 2006 Dec;108(6):1381-1387.
Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial. Obstet Gynecol 2008 Nov;112(5):1029-1036.
Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial. Aust N Z J Obstet Gynaecol 2009 Feb;49(1):77-83.
Treatment of uterine myoma with 5 or 10 mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trial. Eur J Obstet Gynecol Reprod Biol 2012 Apr;161(2):202-208.
Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata. Eur J Obstet Gynecol Reprod Biol 2009 Oct;146(2):215-218.